CTOs on the Move

Oramed

www.oramed.com

 
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.oramed.com
  • 1185 Avenue of the Americas 3rd Floor
    New York, NY USA 10036
  • Phone: 646.844.1164

Executives

Name Title Contact Details

Funding

Oramed raised $50M on 11/03/2021

Similar Companies

Ocuphire Pharma

We are a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire`s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications.

LandsteinerScientific

LandsteinerScientific is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TherapeuticsMD

TherapeuticsMD is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cychem

Cychem is a Thousand Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chimerix

Excerpted from the website: Chimerix discovers, develops and commercializes orally-available, antiviral therapeutics for a broad range of viral diseases, including cytomegalovirus, multi-drug resistant HIV infection and human papilomavirus.